Search

Your search keyword '"Hovi, L."' showing total 10 results
Start Over Author "Hovi, L." Journal blood
10 results on '"Hovi, L."'

1. Addition of Liposomal Daunorubicin (DaunoXome®) to FLAG Significantly Improves Treatment Response in Pediatric Relapsed AML: Final Results From the International Randomised Phase III Study Relapsed AML 2001/01.

Author

Kaspers, G.J.L., primary, Zimmermann, M., additional, Reinhardt, D., additional, Gibson, B., additional, Tamminga, R., additional, Aleinikova, O., additional, Armendariz, H., additional, Dworzak, M., additional, Ha, S., additional, Hovi, L., additional, Maschan, A., additional, Baruchel, A., additional, Bertrand, Y., additional, Razzouk, B., additional, Rizzari, C., additional, Smisek, P., additional, Smith, O., additional, Stark, B., additional, and Creutzig, U., additional

Published
2009
Full Text
View/download PDF

2. Prognostic Significance of Time to Relapse in Pediatric AML: Results from the International Randomised Phase III Study Relapsed AML 2001/01

Author

Kaspers, G.J.L., primary, Zimmermann, M., primary, Reinhardt, D., primary, Gibson, B., primary, Tamminga, R., primary, Armendariz, H., primary, Dworzak, M., primary, Ha, S., primary, Hovi, L., primary, Maschan, A., primary, Baruchel, A., primary, Bertrand, Y., primary, Razzouk, B., primary, Rizzari, C., primary, Smisek, P., primary, Smith, O., primary, Stark, B., primary, and Creutzig, U., primary

Published
2008
Full Text
View/download PDF

3. Long-Term Continuing Second Complete Remission (CCR2) despite Allogeneic Stem Cell Transplantation in CR1: Results from the International Randomised Phase III Study Pediatric Relapsed AML 2001/01

Author

Kaspers, G.J.L., primary, Zimmermann, M., primary, Reinhardt, D., primary, Gibson, B., primary, Tamminga, R., primary, Armendariz, H., primary, Dworzak, M., primary, Ha, S., primary, Hovi, L., primary, Maschan, A., primary, Baruchel, A., primary, Bertrand, Y., primary, Razzouk, B., primary, Rizzari, C., primary, Smisek, P., primary, Smith, O., primary, Stark, B., primary, and Creutzig, U., primary

Published
2008
Full Text
View/download PDF

4. Prognostic Significance of Early Treatment Response in Pediatric Relapsed Acute Myeloid Leukemia: Results from the International Study Relapsed AML 2001/01.

Author

Kaspers, Gertjan J., primary, Zimmermann, M., primary, Reinhardt, D., primary, Tamminga, R., primary, Gibson, B., primary, Armendariz, H., primary, Dworzak, M., primary, Ha, S., primary, Hovi, L., primary, Maschan, A., primary, Philippe, N., primary, Razzouk, B., primary, Rizzari, C., primary, Smisek, P., primary, Smith, O., primary, Stark, B., primary, Will, A., primary, and Creutzig, U., primary

Published
2007
Full Text
View/download PDF

5. Outcome of Infants Less Than One Year of Age with Acute Lymphoblastic Leukemia Treated with the Interfant-99 Protocol.

Author

Pieters, Rob, primary, Schrappe, M., additional, de Lorenzo, P., additional, Hann, I., additional, Vora, A., additional, deRossi, G., additional, Biondi, A., additional, Felice, M., additional, Hovi, L., additional, Mechinaud, F., additional, Szczepanski, T., additional, Ferster, A., additional, Janka, G., additional, Rubnitz, J., additional, Silverman, L., additional, Stary, J., additional, Campbell, M., additional, Mann, G., additional, Suppiah, R., additional, and Valsecchi, M., additional

Published
2006
Full Text
View/download PDF

6. Relapsed Acute Myeloid Leukemia in Children and Adolescents: Interim Report of the International Randomised Phase III Study Relapsed AML 2001/01.

Author

Kaspers, Gertjan J., primary, Zimmermann, M., additional, Fleischhack, G., additional, Tamminga, R., additional, Gibson, Brenda, additional, Armendariz, H., additional, Dworzak, M., additional, Ha, S., additional, Hovi, L., additional, Maschan, A., additional, Philippe, N., additional, Razzouk, Bassem, additional, Rizzari, C., additional, Smisek, P., additional, Smith, Owen, additional, Stark, Batia, additional, Will, A., additional, and Creutzig, Ursula, additional

Published
2006
Full Text
View/download PDF

7. Relapsed Acute Myeloid Leukemia in Children and Adolescents: Interim Results of the International Randomised Phase III Study “Relapsed AML 2001/01”.

Author

Kaspers, Gertjan J., primary, Zimmermann, M., primary, Fleischhack, G., primary, Tamminga, R., primary, Gibson, B., primary, Armendariz, H., primary, Dworzak, M., primary, Ha, S., primary, Hovi, L., primary, Maschan, A., primary, Philippe, N., primary, Razzouk, B., primary, Rizzari, C., primary, Smisek, P., primary, Smith, O., primary, Stark, B., primary, and Creutzig, U., primary

Published
2005
Full Text
View/download PDF

9. Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol

Author

Liisa Hovi, Jan Stary, Maria S. Felice, Andrea Biondi, Ian Hann, Anja Möricke, Marieke H. van der Linden, Jeffrey E. Rubnitz, Rob Pieters, Ajay Vora, Tomasz Szczepański, Maria Grazia Valsecchi, Paola De Lorenzo, Myriam Campbell, Gritta Janka, Thierry Leblanc, Lewis B. Silverman, Alina Ferster, van der Linden, M, Valsecchi, M, De Lorenzo, P, Möricke, A, Janka, G, Leblanc, T, Felice, M, Biondi, A, Campbell, M, Hann, I, Rubnitz, J, Stary, J, Szczepanski, T, Vora, A, Ferster, A, Hovi, L, Silverman, L, Pieters, R, Pediatrics, and Immunology

Subjects
Male, medicine.medical_specialty, Pediatrics, Immunology, Biochemistry, Disease-Free Survival, Leukocyte Count, 03 medical and health sciences, 0302 clinical medicine, Recurrence, Internal medicine, Acute lymphocytic leukemia, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Cumulative incidence, Survival rate, 030304 developmental biology, Gene Rearrangement, B-Lymphocytes, 0303 health sciences, Hematology, business.industry, Remission Induction, Infant, Newborn, leukemia, Myeloid leukemia, Histone-Lysine N-Methyltransferase, Cell Biology, Gene rearrangement, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, 3. Good health, Survival Rate, Regimen, Leukemia, 030220 oncology & carcinogenesis, Female, Neprilysin, business, Myeloid-Lymphoid Leukemia Protein, Follow-Up Studies
Abstract

Acute lymphoblastic leukemia (ALL) diagnosed in the first month of life (congenital ALL) is very rare. Although congenital ALL is often assumed to be fatal, no studies have been published on outcome except for case reports. The present study reports the outcome of 30 patients with congenital ALL treated with the uniform Interfant-99 protocol, a hybrid regimen combining ALL treatment with elements designed for treatment of acute myeloid leukemia. Congenital ALL was characterized by a higher white blood cell count and a strong trend for higher incidence of MLL rearrangements and CD10-negative B-lineage ALL compared with older infants. Induction failure rate was 13% and not significantly different from that in older infants (7%, P = .14), but relapse rate was significantly higher in congenital ALL patients (2-year cumulative incidence [SE] was 60.0 [9.3] vs 34.2 [2.3], P < .001). Two-year event-free survival and survival of congenital ALL patients treated with this protocol was 20% (SE 9.1%). Early death in complete remission and treatment delays resulting from toxicity were not different. The survival of 17% after last follow-up, combined with a toxicity profile comparable with that in older infants, justifies treating congenital ALL with curative intent. This trial was registered at www.clinicaltrials.gov as no. NCT 00015873, and at www.controlled-trials.com as no. ISRCTN24251487.

Published
2009
Full Text
View/download PDF

10. Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol.

Author

van der Linden MH, Valsecchi MG, De Lorenzo P, Möricke A, Janka G, Leblanc TM, Felice M, Biondi A, Campbell M, Hann I, Rubnitz JE, Stary J, Szczepanski T, Vora A, Ferster A, Hovi L, Silverman LB, and Pieters R

Subjects
Antineoplastic Combined Chemotherapy Protocols adverse effects, B-Lymphocytes, Disease-Free Survival, Female, Follow-Up Studies, Gene Rearrangement, Histone-Lysine N-Methyltransferase, Humans, Infant, Newborn, Leukocyte Count, Male, Myeloid-Lymphoid Leukemia Protein genetics, Neprilysin, Precursor Cell Lymphoblastic Leukemia-Lymphoma blood, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Recurrence, Remission Induction, Survival Rate, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
Abstract

Acute lymphoblastic leukemia (ALL) diagnosed in the first month of life (congenital ALL) is very rare. Although congenital ALL is often assumed to be fatal, no studies have been published on outcome except for case reports. The present study reports the outcome of 30 patients with congenital ALL treated with the uniform Interfant-99 protocol, a hybrid regimen combining ALL treatment with elements designed for treatment of acute myeloid leukemia. Congenital ALL was characterized by a higher white blood cell count and a strong trend for higher incidence of MLL rearrangements and CD10-negative B-lineage ALL compared with older infants. Induction failure rate was 13% and not significantly different from that in older infants (7%, P = .14), but relapse rate was significantly higher in congenital ALL patients (2-year cumulative incidence [SE] was 60.0 [9.3] vs 34.2 [2.3], P < .001). Two-year event-free survival and survival of congenital ALL patients treated with this protocol was 20% (SE 9.1%). Early death in complete remission and treatment delays resulting from toxicity were not different. The survival of 17% after last follow-up, combined with a toxicity profile comparable with that in older infants, justifies treating congenital ALL with curative intent. This trial was registered at www.clinicaltrials.gov as no. NCT 00015873, and at www.controlled-trials.com as no. ISRCTN24251487.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results